


DDO-5936

Cat. No.:	HY-139301		
CAS No.:	2355377-13-6		
Molecular Formula:	C ₂₅ H ₂₉ N ₅ O ₄ S		
Molecular Weight:	495.59		
Target:	HSP		
Pathway:	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



BIOLOGICAL ACTIVITY

Description	DDO-5936 is a potent and specific Hsp90-Cdc37 PPI inhibitor. DDO-5936 can be used for the research of colorectal cancer ^[1] .
IC₅₀ & Target	Hsp90-Cdc37 PPI ^[1]
In Vitro	DDO-5936 is a Hsp90-Cdc37 PPI inhibitor with potency and specificity through binding to a critical site on Hsp90 involving Glu47 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	DDO-5936 (0~80 mg/kg; p.o.) shows effect at the high dose group ^[1] . DDO-5936 is well tolerated for the absence of serious weight loss. DDO-5936 high dose groups show that tumor cells in the xenografts decreased significantly. DDO-5936 shows limited oral efficiency ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:	Mice ^[1]
Dosage:	0~80 mg/kg
Administration:	P.o.
Result:	Showed a moderate effect at the high dose group.

REFERENCES

[1]. Wang L, et al. Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer. *J Med Chem.* 2020;63(3):1281-1297.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA